세계의 급성 세균성 피부 및 피부 구조 감염증 시장 보고서(2025년)
Acute Bacterial Skin And Skin Structure Infections Global Market Report 2025
상품코드 : 1824558
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,686,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,665,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,644,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

급성 세균성 피부 및 피부 구조 감염증 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.7%를 나타내 187억 달러로 성장할 전망입니다. 예측 기간의 성장은 세계 역학적 요인, 새로운 치료법 시장 진입, 신속한 진단 도구, 환자 중심 접근법, 치료 지침의 변화 등으로 인한 것으로 예상됩니다. 예측 기간의 주요 동향으로는 환자 인구통계, 항생제 내성 우려, 치료 전략의 진보, 메티실린 내성 황색포도상구균(mrsa)의 유행, 외래 치료의 중시 등이 있습니다.

향후 5년간의 성장률 9.7%라고 하는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 제한으로 인해 프랑스와 한국에서 조달하는 첨단 항생제 및 상처 배양 키트의 가격이 상승하고 치료가 지연되고 병원 비용이 증가하면 미국 의료 시스템이 혼란스러울 수 있습니다. 또한 상호 관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 가해질 수 있습니다.

예상되는 피부 감염증의 급증이 시장 성장의 원동력에 피부 감염증의 유병률 증가가 향후 급성 세균성 피부 및 피부 구조 감염증 시장 성장을 견인할 것으로 예측됩니다. 피부 감염은 박테리아, 곰팡이, 바이러스 등의 미생물이 피부에 침입하여 증식하여 발생하며 다양한 증상과 불쾌감을 초래합니다. 피부 감염 증가는 급성 박테리아 감염과 피부 구조 감염을 관리하기 위한 치료 솔루션, 항생제, 혁신적인 치료법에 대한 수요를 증가시켜 환자가 최적의 치료와 결과를 얻을 수 있도록 합니다. 예를 들어, 2023년 3월 스위스에 본부를 두고 있는 유엔의 전문기관인 세계보건기구(WHO)는 전 세계적으로 약 18억 명의 사람들이 피부질환으로 고통받고 있다고 보고했습니다. 무자비한 열대병(Neglected Tropical Diseases : NTDs)은 약 10%를 차지하며, 곰팡이 감염이 34%, 박테리아 감염이 23%를 차지하며, 종종 큰 사망률로 이어집니다. 따라서 피부 감염의 유병률 상승은 급성 세균성 피부 및 피부 구조 감염증 시장 성장을 가속할 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Acute bacterial skin and skin structure infections (ABSSSIs) represent a category of skin infections caused by bacteria impacting both the skin and underlying tissues, resulting in symptoms such as redness, swelling, pain, and increased warmth in the affected region. Medical interventions, including antibiotic treatments, are employed to prevent complications and facilitate recovery in cases ranging from mild to severe infections.

The primary classifications of acute bacterial skin and skin structure infections encompass hospital-acquired ABSSSIs and community-acquired ABSSSIs. Hospital-acquired ABSSSIs manifest as infections of the skin and underlying tissues that develop due to medical care or hospital stays. Active ingredients in treatments include delafloxacin, vancomycin, ceftaroline fosamil, oritavancin, tedizolid, daptomycin, tigecycline, linezolid, and others, with administration options including oral, parenteral, and topical routes. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, addressing various applications such as cellulitis, abscesses, surgical wounds, and traumatic wounds.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The acute bacterial skin and skin structure infections market research report is one of a series of new reports from The Business Research Company that provides acute bacterial skin and skin structure infections market statistics, including acute bacterial skin and skin structure infections industry global market size, regional shares, competitors with a acute bacterial skin and skin structure infections market share, detailed acute bacterial skin and skin structure infections market segments, market trends and opportunities, and any further data you may need to thrive in the acute bacterial skin and skin structure infections industry. This acute bacterial skin and skin structure infections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute bacterial skin and skin structure infections market size has grown strongly in recent years. It will grow from $11.75 billion in 2024 to $12.9 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to healthcare industry innovation, economic factors, patient population trends, evolving diagnostic methods, clinical trial innovation.

The acute bacterial skin and skin structure infections market size is expected to see strong growth in the next few years. It will grow to $18.7 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to global epidemiological factors, market entry of new therapies, rapid diagnostic tools, patient-centric approach, shifting treatment guidelines. Major trends in the forecast period include patient population demographics, antibiotic resistance concerns, advancements in treatment strategies, prevalence of methicillin-resistant staphylococcus aureus (mrsa), focus on outpatient treatment.

The forecast of 9.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade restrictions may disrupt the U.S. healthcare system by raising prices for advanced antibiotics and wound culture kits sourced from France and South Korea, resulting in delayed treatments and increased hospital costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated surge in the prevalence of skin infections is poised to drive the growth of the market The increasing prevalence of skin infections is anticipated to drive the growth of the acute bacterial skin and skin structure infections market in the future. Skin infections occur when microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, resulting in various symptoms and discomfort. The rise in skin infections generates a heightened demand for therapeutic solutions, antibiotics, and innovative treatments to manage acute bacterial and skin structure infections, ensuring that patients have access to optimal care and outcomes. For example, in March 2023, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that approximately 1.8 billion people worldwide suffer from skin conditions at any given time. Neglected tropical diseases (NTDs) account for about 10% of these cases, with fungal infections representing 34% and bacterial infections 23%, often leading to significant mortality rates. Therefore, the rising prevalence of skin infections is expected to propel the growth of the acute bacterial skin and skin structure infections market.

The increasing prevalence of chronic diseases is also anticipated to boost the growth of the acute bacterial skin and skin structure infections market in the coming years. Chronic diseases are characterized by long-term medical conditions that progress slowly and persist over an extended period, often lasting for years or a lifetime. The growth of chronic diseases contributes to the acute bacterial skin and skin structure infections market by heightening the risk of bacterial skin infections, necessitating increased treatments, hospitalizations, specialized care, research, public awareness, healthcare spending, and tailored interventions for affected individuals. As an illustration, the World Health Organization reported in September 2022 that 74% of the 41 million global deaths caused by non-communicable diseases (NCDs) or chronic diseases annually. The deaths included 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Hence, the increasing prevalence of chronic diseases is a driving force behind the growth of the acute bacterial skin and skin structure infections market.

Major companies operating in the acute bacterial skin and skin structure infections market are strategically focusing on developing innovative single-dose therapies, such as Dalbonova, to gain a competitive edge. Dalbonova is a single-dose therapy designed for convenience and effectiveness, allowing patients to achieve desired results with a potent 1500 mg dose administered once. For example, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company, launched Dalbonova injection, a single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). This injection reduces the risk of hospital-acquired diseases by offering a single-dose treatment and eliminating the need for hospital admissions. It is designed to treat ABSSSI caused by certain gram-positive microorganisms in patients of all ages, including newborns.

In July 2023, Melinta Therapeutics, a pharmaceutical company based in the U.S., partnered with the Biomedical Advanced Research and Development Authority (BARDA) to advance two FDA-approved antibiotics, Baxdela and Minocin, for use in pediatric patients. This collaboration aims to enhance Melinta's pipeline in hematology by leveraging Imago BioSciences' innovative therapies for myeloproliferative neoplasms and other bone marrow diseases, thereby expanding its ability to provide breakthrough treatments for patients facing these serious conditions. The Biomedical Advanced Research and Development Authority is a U.S. government agency focused on developing and acquiring medical countermeasures to safeguard the nation against public health threats.

Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratorios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the acute bacterial skin and skin structure infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The acute bacterial skin and skin structure infections market consists of revenues earned by entities by providing services such as diagnostic testing, surgical procedures for abscess drainage or debridement, inpatient and outpatient healthcare services, and home healthcare and wound care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute bacterial skin and skin structure infections market also includes sales of wound dressings and bandages, medical devices for wound care, vaccines, hydrogen peroxide, and fusidic acid. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Bacterial Skin And Skin Structure Infections Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute bacterial skin and skin structure infections market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for acute bacterial skin and skin structure infections ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acute bacterial skin and skin structure infections market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Acute Bacterial Skin And Skin Structure Infections Market Characteristics

3. Acute Bacterial Skin And Skin Structure Infections Market Trends And Strategies

4. Acute Bacterial Skin And Skin Structure Infections Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Acute Bacterial Skin And Skin Structure Infections Growth Analysis And Strategic Analysis Framework

6. Acute Bacterial Skin And Skin Structure Infections Market Segmentation

7. Acute Bacterial Skin And Skin Structure Infections Market Regional And Country Analysis

8. Asia-Pacific Acute Bacterial Skin And Skin Structure Infections Market

9. China Acute Bacterial Skin And Skin Structure Infections Market

10. India Acute Bacterial Skin And Skin Structure Infections Market

11. Japan Acute Bacterial Skin And Skin Structure Infections Market

12. Australia Acute Bacterial Skin And Skin Structure Infections Market

13. Indonesia Acute Bacterial Skin And Skin Structure Infections Market

14. South Korea Acute Bacterial Skin And Skin Structure Infections Market

15. Western Europe Acute Bacterial Skin And Skin Structure Infections Market

16. UK Acute Bacterial Skin And Skin Structure Infections Market

17. Germany Acute Bacterial Skin And Skin Structure Infections Market

18. France Acute Bacterial Skin And Skin Structure Infections Market

19. Italy Acute Bacterial Skin And Skin Structure Infections Market

20. Spain Acute Bacterial Skin And Skin Structure Infections Market

21. Eastern Europe Acute Bacterial Skin And Skin Structure Infections Market

22. Russia Acute Bacterial Skin And Skin Structure Infections Market

23. North America Acute Bacterial Skin And Skin Structure Infections Market

24. USA Acute Bacterial Skin And Skin Structure Infections Market

25. Canada Acute Bacterial Skin And Skin Structure Infections Market

26. South America Acute Bacterial Skin And Skin Structure Infections Market

27. Brazil Acute Bacterial Skin And Skin Structure Infections Market

28. Middle East Acute Bacterial Skin And Skin Structure Infections Market

29. Africa Acute Bacterial Skin And Skin Structure Infections Market

30. Acute Bacterial Skin And Skin Structure Infections Market Competitive Landscape And Company Profiles

31. Acute Bacterial Skin And Skin Structure Infections Market Other Major And Innovative Companies

32. Global Acute Bacterial Skin And Skin Structure Infections Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Bacterial Skin And Skin Structure Infections Market

34. Recent Developments In The Acute Bacterial Skin And Skin Structure Infections Market

35. Acute Bacterial Skin And Skin Structure Infections Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기